Glossary · Regulation
§ 3a HWG (German Medicinal Products Advertising Act)
In short
Section 3a of the German Medicinal Products Advertising Act (HWG) prohibits advertising for medicines that require authorization but are not authorized. This also applies to indications outside an authorization — one of the reasons why we give no dosages for such substances.
Advertising is defined broadly in German medicines advertising law. A page explaining how much of an unauthorized peptide to take can read like instructions for use — even if the numbers come from studies. We therefore interpret the rule cautiously.
Biohacking Kompakt reports on the evidence and the legal situation, but gives no dosage, no dosing schedules and no sources of supply for unauthorized substances. For authorized substances and nutrients, it states what studies used and which reference values and upper limits authorities recommend.
There is also a substantive reason: where there is no authorization, there is usually no tested dosing schedule either. A number would suggest a certainty that the data do not provide.
No dosage here is not a gap, but a deliberate choice.
Where this comes up in the fact checks
- BPC-157 – No authorized formulation, no validated dosing schedule, no completed phase II trial.
- Low-Dose Naltrexone – A dose cannot be derived from the studies; it belongs in a doctor’s prescription.
Sources
Related terms: Marketing authorization (EMA, FDA, BfArM) · Off-label use · Gray market
Information only, not medical advice. The BK-Score is a subjective assessment according to disclosed rules – not a scientific evaluation. Scoring rules